High-grade glioma with pleomorphic and pseudopapillary features: a single-institution series of three cases Read more about High-grade glioma with pleomorphic and pseudopapillary features: a single-institution series of three cases
Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapy Read more about Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after BCMA-directed chimeric antigen receptor T cell therapy
Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study Read more about Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors. Read more about First-in-Human Phase 1/2 Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors.
Genomic Profiles of Early-Stage Non-Small Cell Lung Cancer Patients, and Association with Pre-Treatment Blood Circulating Tumor DNA Detection and Levels Read more about Genomic Profiles of Early-Stage Non-Small Cell Lung Cancer Patients, and Association with Pre-Treatment Blood Circulating Tumor DNA Detection and Levels
Performance Comparison of RaDaR 1.0 and RaDaR ST Assays for Circulating Tumor DNA Detection Across Solid Tumor Types Read more about Performance Comparison of RaDaR 1.0 and RaDaR ST Assays for Circulating Tumor DNA Detection Across Solid Tumor Types
Performance characterization of a novel whole genome sequencing informed MRD assay Read more about Performance characterization of a novel whole genome sequencing informed MRD assay
Validation of NEO │ PanTracer LBx, a liquid biopsy precision oncology pan-solid tumor comprehensive genomic profiling assay (CGP) Read more about Validation of NEO │ PanTracer LBx, a liquid biopsy precision oncology pan-solid tumor comprehensive genomic profiling assay (CGP)
Non-invasive identification of actionable biomarkers in advanced solid tumors by comprehensive genomic profiling with NEO | PanTracer LBx assay Read more about Non-invasive identification of actionable biomarkers in advanced solid tumors by comprehensive genomic profiling with NEO | PanTracer LBx assay